Author Archives: Jan Paschal

Now that’s an upsizing: UL Solutions (ULS) increased its IPO’s size by 20 percent on Thursday night, April 11, 2024, and priced the deal at $28.00 – near the top of its range – to raise $946.4 million. The company’s parent, ULSE Inc., sold 33.8 million shares – up from 28.0 million in the prospectus. […]

PACS Group (PACS) upsized its IPO at pricing to 21.43 million shares – up from 19.05 million shares – and priced the deal at $21.00 – the mid-point of its $20.00-to-$22.00 range – to raise $450.0 million on Wednesday night, April 10, 2024. PACS Group’s stock opened today – Thursday, April 11, 2024 – on the […]

Household name UL Solutions Inc. (ULS Proposed) and nursing home operator PACS Group (PACS Proposed) share the IPO marquee this week with plans to raise a combined $1.2 billion. Both are New York Stock Exchange listings. Both are profitable companies whose IPOs are set to price this week. These two big IPOs are part of the […]

Ibotta Inc. (IBTA Proposed), a Denver digital advertising rewards company, filed the terms for its IPO early today – Monday, April 8, 2024: 5.63 million shares (5,625,000 shares) at the eye-popping price range of $76.00 to $84.00 to raise $450.0 million, based on mid-point pricing at $80.00. This is a New York Stock Exchange listing. […]

Contineum Therapeutics (CTNM), a Phase 1/Phase 2 biotech, priced its downsized IPO at $16.00 – the low end of its $16.00-to-$18.00 range – on Thursday night, April 4, 2024. The deal’s size was slashed to 6.88 million shares (6,875,000 shares) – down from 8.8 million shares in the prospectus. Contineum Therapeutics raised $110.0 million – well below […]

UL Solutions Inc. (ULS Proposed) set the terms and the date for its $770 million IPO early today – Tuesday, April 2, 2024 – in a post-Easter parade of deals that could raise more than $1 billion. The product testing and safety standards company disclosed in its S-1/A filing today that it plans to offer […]

April got underway for the IPO market early today – Monday, April 1, 2024 –  with the launch of Phase I biotech Contineum Therapeutics (CTNM Proposed). The San Diego-based biotech, which is developing drugs to treat progressive MS (multiple sclerosis) and IPF (idiopathic pulmonary fibrosis), plans to price its $149.6 million IPO later this week to […]

Boundless Bio (BOLD) priced its IPO at $16.00 – the mid-point of its range – on just 6.25 million shares – the number of shares in the prospectus – to raise $100.0 million on Wednesday night, March 27, 2024. The Phase 1/Phase 2 cancer biotech’s stock sank in its first day of NASDAQ trading  on Thursday, March […]

Cancer biotech Boundless Bio (BOLD Proposed) leads the short playlist for the four-day holiday week of March 25, 2024, with its $100 million IPO. The U.S. stock market will be closed Friday, March 29, for Good Friday, which marks the start of the three-day Easter holiday weekend. The rest of this week’s IPO Calendar consists […]

Auna S.A. (AUNA), a Latin American healthcare provider backed by Peru’s private equity firm Enfoca, priced its IPO at $12.00 – $1.00 below its $13.00-to-$15.00 range – on 30.0 million shares- the number of shares in the prospectus – to raise $360.0 million on Thursday night (March 21, 2024). Auna raised $60 million less than […]